Amgen Inc.’s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.

The benefits of obesity drugs such as Novo Nordisk’s Wegovy on healthcare systems in countries such as the United States are so significant that the expected entry of rival drugs will not hurt its margins, CEO Lars Jorgensen told Reuters on Tuesday.

Novo Nordisk shared that its clinical trial of CagriSema, a combination injection for overweight people with type II diabetes, resulted in a 15.6% body weight reduction compared to the drugs dosed individually.